Abbreviated DAPT after PCI with drug coated balloons in acute coronary syndromes - insights from the SWEDEHEART registry [0.03%]
来自SWEDEHEART登记处的急性冠脉综合征药物涂层球囊经皮冠状动脉介入治疗后缩短DAPT时程的启示
Anton Håkansson,Sacharias von Koch,Axel Dahlgren et al.
Anton Håkansson et al.
Aims: The absence of stent implantation when using drug-coated balloons (DCB) may decrease the required duration of dual antiplatelet therapy (DAPT). In the light of this, this study aimed to evaluate outcomes for patient...
Effect of intensive blood pressure and blood glucose control on cardiovascular outcomes driven by reductions in cardiovascular death and nephropathy: Win ratio analysis of ADVANCE Trial [0.03%]
降压和降糖治疗对心血管死亡及肾病减少的心血管预后影响的赢比分析：ADVANCE研究
Severine Bompoint,Laurent Billot,Anushka Patel et al.
Severine Bompoint et al.
Background and aims: To re-analyse the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation) trial using the win ratio approach to better understand the relative ...
Initiation of Eplerenone vs Spironolactone and All-cause Mortality in HFrEF: Linked Database Study [0.03%]
用于心力衰竭患者的依普利酮与螺内酯的启动及全因死亡率：数据库 linkage研究
Henrik Svanström,Anders Hviid,Björn Pasternak
Henrik Svanström
Aims: Mineralocorticoid receptor antagonists (MRAs) are recommended as part of guideline-directed medical therapy for heart failure with reduced ejection fraction (HFrEF). The comparative effectiveness of spironolactone a...
From Stabilization to Silencing in Transthyretin Amyloid Cardiomyopathy: Why Sequencing Should Be Treat-to-Trajectory, Not "One-and-Done [0.03%]
遗传性转甲状腺素蛋白心肌病从稳定到静止的治疗策略：为什么基因治疗应该采用“疗效追踪”模式，而不仅仅是“一次完成”
Arif Albulushi,Tasneem Al Rashdi,Hatem Al-Farhan et al.
Arif Albulushi et al.
Implementation of novel antithrombotic treatment strategies and outcome improvements in patients with myocardial infarction and atrial fibrillation over 20 years: a nationwide cohort study [0.03%]
20年来的新型抗血栓治疗策略及其对心肌梗死合并房颤患者预后改善的全国队列研究实施
Christian Losciale,Lars Lindhagen,Lars Wallentin et al.
Christian Losciale et al.
Background: Patients with acute myocardial infarction (MI) and atrial fibrillation (AF) present challenges in antithrombotic treatment. Effects of newer treatment strategies on outcomes remain uncertain. We assessed imple...
Beyond the review: additional non-oncologic drugs with clinically significant cardiovascular effects [0.03%]
超越综述：其他具有重要的心血管效应的非抗肿瘤药物
Lorenz Van der Linden,Thomas Vanassche
Lorenz Van der Linden
Monoclonal antibodies targeting IL-5/5R or IL-4/13 pathways in eosinophilic myocarditis: a single-center experience and systematic literature review [0.03%]
抗IL-5/IL-5受体和抗IL-4/IL-13途径单克隆抗体治疗嗜酸性粒细胞心肌炎：单一中心经验和系统文献回顾
A S Giordani,C Menghi,A Baritussio et al.
A S Giordani et al.
Aims: Eosinophilic myocarditis (EM) is a rare inflammatory heart disease often associated with eosinophilic granulomatosis with polyangiitis or hypereosinophilic syndrome. While anti-IL-5/5R and anti-IL-4/13 monoclonal an...
Response to SGLT2 Inhibitors in Heart Failure With Tricuspid Regurgitation: Clinical Interpretation and Future Directions [0.03%]
三尖瓣反流心力衰竭患者使用钠葡萄糖共转运体-2抑制剂的临床反应：解读与未来方向
Ranel Loutati,Viana Copeland,Shir Elimeleh et al.
Ranel Loutati et al.
SGLT2 Inhibitors in Heart Failure With Tricuspid Regurgitation: Clinical Interpretation and Future Directions [0.03%]
心力衰竭三尖瓣反流钠葡萄糖协同转运蛋白-2抑制剂临床解读与未来方向
Weikai Dong,Yebin Zhou,Junying Jiang
Weikai Dong